Izdelki za oprema za rešitve (10)

An effective bactericidal antibiotic for the treatment of infections caused by gram-negative and gram-positive bacteria. It has a bactericidal effect on proliferating pathogenic microorganisms, preventing the enzymatic synthesis of the bacterial cell wall.

An ultra-wide range of antibacterial activity includes practically all significant gram-positive (+) and gram-negative (-) aerobic and anaerobic microorganisms. Non-neurotoxic. Used for de-escalation therapy of serious infections of lower respiratory tract, intraabdominal infections, gynecological infections, skin and soft tissue infections, meningitis, septicemia, empiric treatment in patients with neutropenia, as monotherapy or in combination with antiviral or antifungal pharmaceutical products.

A highly potent carbapenem antibiotic drug. Active against gram-positive (+) and gram-negative (-) aerobic and anaerobic bacteria. Several times more active against Pseudomonas aeruginosa compared to meropenem and imipenem/cilastatin. Used in treatment of hospital-acquired (nosocomial) pneumonia, including ventilator-associated pneumonia; complicated intraabdominal infections; complicated infections of urinary system, including complicated and uncomplicated pyelonephritis, particularly pyelonephritis with accompanying bacteremia.

The active ingredient of Claribaccin is clarithromycin. Clarithromycin is a semisynthetic macrolide antibiotic derived by substitution of CN3O hydroxyl group by (OH) group in the 6th position of the lactone ring of erythromycin, more precisely, clarithromycin is 6-Omethylerythromycin A. The mechanism of action of clarithromycin is based on binding to 50S ribosomal subunit of sensitive bacteria, which prevents the translocation of activated amino acids. Clarithromycin inhibits intracellular protein synthesis of microorganisms sensitive thereto and thereby exerts its antibacterial action.

Reliable choice in treatment of acquired microbial resistance. Especially active against gram-negative (-) bacteria. Most active against Pseudomonas aeruginosa, Acinetobacter baumannii, Citrobacter spp. Used parenterally in treatment of serious infections of lower respiratory tract and urinary system when widely used systemic antibiotics are ineffective because of development of bacterial resistance. Inhalational administration is recommended for patients with mucoviscidosis.

Gold standard” of monotherapy of serious infections in inpatient settings. Active against a wide range of gram-positive (+) and gram-negative aerobic bacteria, majority of anaerobic bacteria. Used in therapy of serious polymicrobic infections of lower respiratory tract, urinary system infections, intraabdominal infections, gynecological infections, skin and soft tissue infections, bone and joint infections, endocarditis.

New highly effective glycopeptide antibiotic for systemic use with bactericidal activity against a wide range of gram-positive (+) bacteria, multiresistant nosocomial strains, including VanB-phenotype VRE. It can be administered once daily intramuscularly or intravenously as a bolus injection. The antibiotic has low toxicity and favorable tolerability. It is used in treatment of serious respiratory and urinary tract infections, skin and soft tissue infections, bone and joint infections, septicemia, endocarditis, peritonitis, infectious colitis.

First antibiotic of the glycopeptide group. Highly active against a wide range of gram-positive (+) microorganisms, including methicillin-resistant strains. Used in treatment of endocarditis, sepsis, skin and soft tissue infections, bone and joint infections (including osteomyelitis), CNS infections (including meningitis), infections of lower respiratory tract, pseudomembranous colitis, enterocolitis.

Reliable choice in treatment of acquired microbial resistance. Especially active against gram-negative (-) bacteria. Most active against Pseudomonas aeruginosa, Acinetobacter baumannii, Citrobacter spp. Used parenterally in treatment of serious infections of lower respiratory tract and urinary system when widely used systemic antibiotics are ineffective because of development of bacterial resistance. Inhalational administration is recommended for patients with mucoviscidosis.

Antituberculous polypeptide antibiotic with low toxicity and and good tolerance. It is used for the treatment of drug-resistant forms of pulmonary tuberculosis.